Laure VINCENT | Immunology Cellular Interactions | Best Research Article Award

Posted on by sciencefather

Dr. Laure VINCENT | Immunology Cellular Interactions | Best Research Article Award

Dr. Laure VINCENT, CHU de Montpellier , France

Dr. Laure Vincent is a distinguished hematologist at the CHU de Montpellier, specializing in clinical hematology. With a focus on multiple myeloma and stem cell transplantation, she is recognized for her extensive research and clinical expertise. She is affiliated with the Hôpital St Eloi, Montpellier, where she actively contributes to advancing treatments in hematologic malignancies. Dr. Vincent has a profound commitment to patient care and an established career in the hematology field, making notable contributions to both the scientific and medical communities.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Extensive Research Contribution: Dr. Vincent has made significant contributions to the field of hematology, with numerous publications in renowned journals such as Leukemia, Bone Marrow Transplantation, Haematologica, and Blood Cancer Journal. Her research has focused on critical topics like multiple myeloma, hematopoietic stem cell transplantation, and the treatment of myelodysplastic syndromes.

  2. Innovative and Impactful Studies: Many of her studies highlight novel findings that contribute to the understanding and management of hematological diseases. For instance:

    • Her research on insulin as a myeloma cell growth factor (Leukemia, 2010) opened new avenues for treatment approaches.

    • The exploration of the therapeutic window for myeloma relapse after high-dose melphalan and stem cell transplantation (Oncotarget, 2012) shows an in-depth understanding of patient care in a post-transplant setting.

    • The retrospective study on hematopoietic stem cell transplantation in multiple myeloma patients from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (Biol Blood Marrow Transplant, 2015) has crucial implications for treatment strategies in myeloma.

  3. Multidisciplinary Collaboration: Dr. Vincent has worked extensively with international research teams, reflecting her ability to collaborate and contribute to large-scale studies and multicenter trials. This is evident in studies such as the ones published with the Société Française de Greffe de Moelle et de Thérapie Cellulaire and the Eurocord/ALWP-EBMT study.

  4. Comprehensive Educational Impact: In addition to her research, Dr. Vincent has contributed significantly to the education and training of healthcare professionals, particularly in oncology and hematology. Her work in developing educational content for nurses and students in the field of Onco-Hematology demonstrates her commitment to advancing clinical knowledge.

Areas for Improvement:

  1. Wider Dissemination of Findings: While Dr. Vincent’s research has been highly impactful within the specialized field of hematology, her findings could benefit from broader dissemination. This could include collaborations with non-medical fields or publishing findings in more general medical journals to reach a wider audience.

  2. Focus on Translational Research: Although Dr. Vincent’s research primarily focuses on clinical outcomes and therapies, incorporating more translational research—bridging the gap between bench and bedside—could further enhance her work. Research on biomarkers for early detection, for example, would benefit the field of personalized medicine.

  3. Long-Term Impact Studies: Some of Dr. Vincent’s studies are focused on the immediate or short-term effects of therapies. It would be valuable to see more research that addresses the long-term outcomes of treatments in hematological diseases, especially in terms of quality of life and survival rates over decades.

Education:

Dr. Vincent’s educational journey began with secondary studies at the Lycée International de Grenoble, where she earned a scientific baccalaureate with distinction in 1999. She then pursued her medical degree at the University of Grenoble (1999-2006), followed by specialized training in hematology. Dr. Vincent is fluent in English, holding Cambridge Certificates in Advanced and Proficiency English. Additionally, she holds certifications in business English and advanced clinical training in hematology.

Experience:

Dr. Laure Vincent has extensive clinical experience in the field of hematology, particularly in hematopoietic stem cell transplantation. She has contributed to several impactful research studies, focusing on treatments for hematological malignancies like multiple myeloma and myelodysplastic syndromes. Dr. Vincent has published extensively in reputable journals, authored chapters in medical books, and presented her work at various prestigious international conferences, demonstrating her authority in the field. She also serves as an educator, contributing to the training of future healthcare professionals.

Research Focus:

Dr. Vincent’s research primarily focuses on hematological cancers, including multiple myeloma, myelodysplastic syndromes, and stem cell transplantation. Her studies explore innovative therapies, relapse prevention strategies, and mechanisms of drug resistance in these malignancies. Notable research topics include the use of monoclonal antibodies, the role of the bone marrow microenvironment, and the improvement of outcomes following hematopoietic stem cell transplantation. Her work aims to develop targeted therapies to improve patient survival rates and quality of life.

Publications Top Notes:

  1. “Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation” (Leukemia, 2010) 🧬

  2. “Malignant plasma cells responsible for Multiple Myeloma relapse are detectable and survive seven days after high dose melphalan and stem cell transplantation” (Oncotarget, 2012) 🧪

  3. “Allo-SCT for philadelphia negative myeloproliferative neoplasms in blast phase” (Bone Marrow Transplant, 2014) 💉

  4. “HLA-matched Allogeneic SCT improves outcome of higher risk MDS” (Leukemia, 2015) 🩸

  5. “Drug metabolism and clearance system in tumor cells of patients with multiple myeloma” (Oncotarget, 2015) 💊

  6. “Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation” (Haematologica, 2015) 👩‍⚕️

  7. “Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia” (Leukemia, 2015) 🔬

  8. “Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study” (Biol Blood Marrow Transplant, 2015) 🏥

  9. “Autologous Stem Cell Transplantation For Relapsed/Refractory Diffuse Large B Cell Lymphoma” (Bone Marrow Transplant, 2015) 🔄

  10. “Bing-Neel syndrome as a rare complication of Waldenström’s macroglobulinemia” (Haematologica, 2015) 🧠

Conclusion:

Dr. Laure Vincent’s research is exceptional, with a proven track record in advancing knowledge and treatment options in hematology. Her ability to lead large-scale studies, her contributions to important clinical findings, and her dedication to educating future healthcare professionals make her highly deserving of the “Best Research Article Award.” While there is always room for expanding the scope of research to include more translational and long-term impact studies, her work undoubtedly stands out as a significant contribution to hematological science.

Mehmet Ali Karaselek | Immunology | Best Researcher Award

Posted on by sciencefather

Dr. Mehmet Ali Karaselek | Immunology | Best Researcher Award

Dr. Mehmet Ali Karaselek , Necmettin Erbakan Üniversitesi , Turkey

Dr. Mehmet Ali Karaselek is an accomplished immunologist, widely known for his work on genetic immunodeficiencies and immune system disorders. He holds a significant position in clinical immunology, focusing on T-cell subsets, immune profiling, and the molecular mechanisms behind various immune diseases. His expertise extends to autoimmune diseases, cancers, and rare immunodeficiencies such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency. His extensive research has contributed to a deeper understanding of immune system dysfunctions and therapeutic implications, especially in immune deficiency conditions. Dr. Karaselek is also involved in training future scientists and physicians, combining his expertise in molecular immunology with clinical practice to improve diagnostic and therapeutic approaches in immunology. His publications and ongoing research projects continue to enrich the field of clinical immunology and immunogenetics.

Publication Profile:

Orcid

Strengths for the Award:

  1. Expertise in Immunology: Dr. Karaselek has contributed significantly to understanding immune system disorders, particularly immune deficiencies and their relationship with genetic mutations. This is reflected in several of his articles related to immune cell subsets, immune disorders like immunodeficiencies (e.g., CD19 deficiency, DCLRE1C deficiency), and T-cell and NK-cell functions.

  2. Innovative Research Areas: His focus on transcription factor and cytokine expression in various T-cell subsets, as well as his recent work in cancer-related therapies using pillar[5]arene derivatives, illustrates a strong grasp of cutting-edge topics in both immunology and drug development.

  3. Collaboration Across Fields: Dr. Karaselek’s research spans multiple fields, including cancer research, immunodeficiencies, and genetic disorders, showcasing his ability to work across disciplines. He has collaborated with many researchers on complex issues like genetic mutations and immune dysfunctions, highlighting his team-based approach and leadership in the research community.

  4. Contributions to Clinical Immunology: His numerous articles in high-impact journals, such as the Journal of Clinical Immunology, Expert Review of Clinical Immunology, and APMIS, demonstrate his dedication to advancing clinical research, improving diagnostics, and understanding immune system pathologies.

  5. High Publication Frequency: The volume of publications and the consistency of research output in recent years (2023–2025) reflects a high level of productivity and dedication to his field. This output signifies Dr. Karaselek’s capacity to consistently push the boundaries of immunology research.

Areas for Improvement:

  1. Broader Global Recognition: While Dr. Karaselek’s publications are substantial, increasing the international impact of his work through higher-profile collaborations or by engaging in high-impact, globally recognized studies could further elevate his standing in the scientific community.

  2. Interdisciplinary Impact: Although his work covers a broad spectrum, a more explicit focus on interdisciplinary applications of his research, especially between immunology, genomics, and personalized medicine, could help translate his research findings into clinical practice more effectively.

  3. Public Engagement: Engaging in public-facing work such as writing for science outreach or sharing research insights in a more accessible format could further enhance his visibility and allow his discoveries to have a broader societal impact.

Education:

Dr. Mehmet Ali Karaselek earned his medical degree from a prestigious institution, followed by specialized training in clinical immunology. He furthered his education with a focus on advanced immunology and immunogenetics, completing multiple certifications and postdoctoral research programs. His early academic interests were rooted in understanding the molecular basis of immune system disorders, which led him to pursue an in-depth study of genetic immunodeficiencies. He has continually sought to enhance his expertise by participating in various national and international conferences and workshops on immunology. Throughout his career, Dr. Karaselek has combined clinical education with practical experience, which has enabled him to contribute effectively to both scientific research and patient care. His comprehensive educational background has been instrumental in his ability to lead complex research projects, investigate the immunological aspects of rare diseases, and educate others in the field.

Experience:

Dr. Mehmet Ali Karaselek has extensive experience in clinical immunology, with a focus on the genetic and molecular mechanisms of immune disorders. He has worked in academic and clinical settings, leading research projects and contributing to major breakthroughs in immunodeficiencies and autoimmune diseases. Over the years, he has collaborated with a wide range of medical professionals, contributing to the diagnosis and treatment of rare genetic conditions such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency. His expertise also spans cellular immunology, where he has conducted research on T-cell subsets and cytokine expression. His clinical experience, combined with his research background, has positioned him as a leader in the immunology community, with a focus on improving immunogenetic diagnostic techniques. Dr. Karaselek has also mentored numerous students and professionals, further advancing the field through knowledge dissemination and collaboration.

Research Focus:

Dr. Mehmet Ali Karaselek’s research focuses on the molecular and genetic mechanisms underlying immune system disorders, particularly in the context of immunodeficiencies and autoimmune diseases. He is deeply involved in studying T-cell subsets, immune cell profiling, and cytokine expression in patients with rare genetic mutations. His work has shed light on the pathophysiology of conditions such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency, with the aim of improving diagnosis and treatment options. Dr. Karaselek is also interested in the immunological aspects of cancer, having explored immune cell interactions in various cancer types. His research contributions extend to immune modulation, studying how intensive physical activity like weightlifting affects immune cells. By integrating clinical observations with laboratory-based research, Dr. Karaselek seeks to bridge the gap between basic science and clinical practice, providing new insights into immune system functionality and dysfunctions.

Publications Top Notes:

  1. Investigation of Transcription Factor and Cytokine Gene Expression Levels in Helper T Cell Subsets Among Turkish Patients Diagnosed with ICF2 and ICF3 Syndrome 🧬🧪
  2. Association of NK cell subsets and cytotoxicity with FCGR3A gene polymorphism in functional NK cell deficiency 🧫🔬
  3. Changes in T-cell subsets occur in interstitial lung disease and may contribute to pathology via complicated immune cascade 🫁🩸
  4. Effect of intensive training on immune system cells in elite female weightlifters 🏋️‍♀️🦠
  5. Evaluation of transcription factors and cytokine expressions of T-cell subsets in CD19 deficiency and their possible relationship with autoimmune disease 🤧🔬
  6. Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation 🧬🔬
  7. Variable clinical presentation of hypomorphic DCLRE1C deficiency from childhood to adulthood 👶👨‍⚕️
  8. Water-soluble Pillar[5]arene-based drug candidates for lung and breast cancer 🧪🌊
  9. Could immune cells be associated with nephropathy in Fabry disease patients? 💉🩺
  10. Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines 🧬💊

Conclusion:

Dr. Mehmet Ali Karaselek is a highly qualified and productive researcher with significant contributions in immunology and genetics. His vast experience, innovative approaches, and contributions to key scientific areas make him an ideal candidate for the Researcher for Best Researcher Award. Enhancing his global influence and promoting public engagement in his research would be valuable next steps.

Guangxun Meng | Cancer Immunology | Cancer Cell Biology Award

Posted on by sciencefather

Prof. Guangxun Meng | Cancer Immunology | Cancer Cell Biology Award

Prof. Guangxun Meng , Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences , China

Guangxun Meng is the Lab Chief of the Innate Immunity Lab at the Shanghai Institute of Immunity and Infection, CAS, China. He specializes in mucosal immunology and inflammasome research, with a focus on barrier organs such as the gut, lung, and skin. His work is instrumental in understanding viral infections, inflammation, and cancer, particularly within the respiratory system and gut. With numerous high-impact publications, Guangxun’s contributions to immunology have significantly advanced understanding in innate immunity and the inflammasome’s role in disease. His ongoing research projects include exploring novel therapeutics for cancer suppression and viral infections.

Publication Profile:

Google Scholar

Strengths for the Award:

Dr. Guangxun Meng has made substantial contributions to the fields of mucosal immunology, inflammation, and cancer, particularly through his work on the inflammasome and innate immunity. His research has been pivotal in understanding the roles of NLRP3 and IL-18 in immune responses and cancer suppression. Dr. Meng’s work has led to significant advancements, such as the discovery of short IL-18 and its mobilization of NK cells to suppress tumor growth. His innovative work, which links microbiota, inflammasomes, and viral immunity, has been published in prestigious journals like Nature Immunology and Nature Communications. The breadth of his patents, including those targeting viral infections, further highlights his innovative contributions to the field.

Areas for Improvement:

While Dr. Meng’s research has made significant strides in understanding immune responses in cancer, further investigation into the therapeutic applications of his findings would be beneficial. Expanding collaborations with clinical researchers could bridge the gap between basic science and clinical oncology, potentially leading to novel treatment options.

Education:

Guangxun Meng earned his advanced degrees at leading institutions, where he developed a strong foundation in immunology and molecular biology. He completed his postdoctoral training in immunology and infectious diseases, deepening his understanding of immune responses to viral infections and their regulation in mucosal tissues. Throughout his career, he has focused on integrating experimental immunology with clinical insights to discover new therapeutic strategies, making him a prominent figure in his field.

Experience:

Guangxun Meng’s extensive research experience spans key roles in both academia and collaborative projects with the biotech industry. As Lab Chief at the Shanghai Institute of Immunity and Infection, he leads a team focused on understanding the mechanisms of mucosal immunity and inflammation. His research spans multiple areas, including cancer immunotherapy, viral infections, and the inflammasome’s role in diseases like sepsis. Over the years, Guangxun has worked with leading immunologists worldwide, contributing significantly to research on innate immunity, microbial interactions, and cancer biology.

Awards and Honors:

Guangxun Meng has received numerous accolades throughout his career for his groundbreaking contributions to immunology and cancer research. He is a respected member of several prestigious scientific societies, including the Society for Mucosal Immunology and the American Association of Immunologists. His work has led to significant advances in the fields of inflammation and viral infections, and his lab continues to receive recognition for the potential clinical applications of its research. His contributions to immunology have made him a leading expert in the study of inflammasomes and mucosal immunity.

Research Focus:

Guangxun Meng’s primary research focuses on mucosal immunology, inflammasome activation, and innate immunity. His work investigates the immune responses in barrier organs like the gut, skin, and lungs, particularly in relation to viral infections, inflammation, and cancer. He is exploring the therapeutic potential of novel molecules like short IL-18 and the role of microbiota-derived metabolites, such as short-chain fatty acids, in immune modulation. His lab’s research also includes the development of new strategies to target inflammasome activation and improve responses to infections and cancer.

Publications Top Notes:

  1. Short IL-18 generated by caspase-3 cleavage mobilizes NK cells to suppress tumor growth – Nature Immunology 📄
  2. Interleukin-1 prevents SARS-CoV-2-induced membrane fusion to restrict viral transmission – eLife 🦠
  3. Anti-influenza activity of CPAVM1 protease secreted by Bacillus subtilis LjM2 – Antiviral Res. 💊
  4. Antibody-mediated spike activation promotes cell-cell transmission of SARS-CoV-2 – PLoS Pathogens 🧪
  5. cFLIPS regulates alternative NLRP3 inflammasome activation in human monocytes – Cell Mol Immunol 💡
  6. TRAF6-TAK1-IKKβ pathway mediates TLR2 agonists activating “one-step” NLRP3 inflammasome – Cytokine 🔬
  7. TAK1 Deficiency in Macrophages Increases Host Susceptibility to Leishmania Infection – Infectious Microbes & Diseases 🦠
  8. Function of NLRP3 in Anti-influenza Viral Infection – Viruses 🦠
  9. Microbiota-derived acetate enhances host antiviral response via NLRP3 – Nature Communications 🌿
  10. SARS-CoV-2 spike engagement of ACE2 primes S2’site cleavage and fusion initiation – Proc Natl Acad Sci USA 🦠

Conclusion:

Dr. Guangxun Meng is highly deserving of the Research for Cancer Cell Biology Award. His pioneering work in immunology, inflammasomes, and cancer biology represents a critical contribution to the understanding of immune responses in cancer. His research promises to have significant implications for both cancer therapy and infectious disease control.

 

 

 

Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Posted on by sciencefather

Prof. Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Prof. Yimin Zhu , Suzhou Institute of Nanotechnology, Chinese Academy of Sciences , China

Prof. Yimin Zhu is a distinguished researcher in bioengineering, specializing in cancer therapies, biomaterials, and peptide screening platforms. With a background in both clinical medicine and biotechnology, she bridges the gap between medical applications and cutting-edge biotechnological innovations. Prof. Zhu completed her master’s in Clinical Medicine from Tianjin Medical University in 1996 and a Ph.D. in Biochemistry from the National University of Singapore in 2005. She has made significant contributions to cancer immunotherapy, drug delivery systems, and biomarker identification. Prof. Zhu’s work has led to over 30 first-author/co-corresponding publications in leading scientific journals, and she holds more than 20 patents. She currently holds a professorship at Suzhou Institute of Nano-Tech and Nano-Bionics, CAS, where her research continues to advance cancer treatments through novel molecular mechanisms and drug delivery platforms.

Publication Profile:

Scopus

Strengths for the Award:

  1. Interdisciplinary Expertise: Prof. Yimin Zhu has a unique blend of clinical medicine and advanced biotechnology expertise, making her well-suited to bridge the gap between medical practice and cutting-edge cancer research. Her background in both the clinical and research fields allows her to tackle cancer therapies from multiple angles.
  2. Impactful Research: Prof. Zhu’s research focuses on critical areas in cancer therapy, such as peptide-based immunotherapy, tumor mechanisms, drug delivery systems, and biomarker discovery. She has published over 30 high-impact papers in leading journals, showcasing her leadership in the field.
  3. Innovative Contributions: She has made substantial contributions to developing peptide-based bispecific CAR T cells and innovative drug delivery systems, with several patents granted. These innovations hold great promise for advancing cancer therapy and improving patient outcomes.
  4. Support and Funding: Prof. Zhu has successfully secured substantial research funding, including multiple grants from the National Natural Science Foundation of China, supporting her groundbreaking research in cancer immunotherapy and biomaterial development.

Areas for Improvement:

  1. Broader Outreach: Although Prof. Zhu has made impressive advancements in cancer research, expanding her work’s visibility to a broader audience in the medical and biotechnology communities, as well as among the general public, could increase the impact of her innovations.
  2. Collaboration and Mentorship: Further expanding interdisciplinary collaborations, particularly with social scientists or clinicians in oncology, could strengthen the practical application of her research and increase its translation into clinical practice. Additionally, mentoring young women in STEM could increase her contribution to fostering diversity in the field.
  3. Public Engagement: Enhancing communication efforts to present her research in a more accessible format for non-experts could be a significant avenue for impact, particularly in terms of attracting additional funding and public interest in her cancer-focused work.

Education:

Prof. Yimin Zhu’s educational journey reflects her interdisciplinary approach to bioengineering and medical science. She earned her Master’s degree in Clinical Medicine from Tianjin Medical University in 1996, where she initially focused on medical practice, gaining hands-on experience as a resident and consultant in Neurology. Her passion for scientific research led her to pursue a Ph.D. in Biochemistry from the National University of Singapore, completed in 2005. This transition to biochemistry allowed her to explore molecular biology, cancer research, and biotechnology. Prof. Zhu’s postdoctoral work at the University of California, Santa Barbara, in Chemical Engineering, further honed her expertise in nanotechnology, bioengineering, and therapeutic innovations. This broad educational foundation, combining clinical experience with cutting-edge research, has uniquely positioned her as a leader in cancer bioengineering and drug delivery systems.

Experience:

Prof. Yimin Zhu’s diverse experience spans both clinical medicine and high-impact research. Between 1996 and 2000, she worked as a resident and consultant doctor in Neurology, which provided a strong foundation in patient care and medical science. Transitioning to research, she served as a research fellow at the National University of Singapore from 2003 to 2005, focusing on biochemistry and cancer-related molecular mechanisms. Prof. Zhu further developed her expertise during her postdoctoral training in the Chemical Engineering Department at the University of California, Santa Barbara, where she explored the intersection of chemical engineering, nanotechnology, and therapeutic interventions. Since joining the Suzhou Institute of Nano-Tech and Nano-Bionics in 2008, she has been a professor, where she leads innovative research in peptide-based cancer therapies, immunotherapy, and drug delivery systems. Her extensive academic background and practical experience have earned her numerous patents and substantial research funding.

Research Focus:

Prof. Yimin Zhu’s research primarily focuses on bioengineering for cancer treatment, peptide screening platforms, and targeted drug delivery systems. Her work involves identifying molecular mechanisms behind tumor cell behavior and developing innovative methods for cancer diagnosis and therapy. She is dedicated to advancing cancer immunotherapy, particularly through the development of peptide-based bispecific CAR T cells targeting key proteins like EGFR and tumor stroma. Prof. Zhu’s research aims to enhance the efficacy of cancer treatments while minimizing side effects. Her studies also explore the development of smart delivery systems, such as extracellular vesicle-based nanodrugs, to improve the precision and effectiveness of drug delivery to tumor sites. Additionally, her work delves into the identification of cancer biomarkers, offering new ways to predict tumor metastasis and optimize treatment regimens. By combining molecular biology, nanotechnology, and biotechnology, Prof. Zhu’s research holds great promise for advancing personalized cancer care.

Publications Top Notes:

  • The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy 🧬
  • Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress 💉
  • Natural killer cells contribute to ‘hot’ tumor regression in the allergic inflammatory environment 🦠
  • Identification of cancer protein biomarker based on cell specific peptide and its potential role in predicting tumor metastasis 🔬
  • Extracellular Vesicle‐Based Nanodrug Delivery 💊
  • Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin 🧫
  • Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity 🌿
  • Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety 🦠
  • Smart delivery of poly-peptide composite for effective cancer therapy 💡
  • The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells ⚙️

Conclusion:

Prof. Yimin Zhu’s research excellence, particularly in cancer therapy, peptide-based immunotherapy, and novel drug delivery systems, positions her as a highly deserving candidate for the Research for Women Researcher Award. Her interdisciplinary approach, groundbreaking innovations, and leadership in publishing high-impact scientific papers make her a trailblazer in the field of bioengineering. By addressing the areas for improvement, particularly in outreach and mentorship, Prof. Zhu could amplify her contributions even further, inspiring the next generation of women scientists and advancing the fight against cancer.